Log in to save to my catalogue

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c3477c962caf480e9537b3db7eabd49c

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

About this item

Full title

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

Publisher

London: Nature Publishing Group UK

Journal title

Nature communications, 2022-01, Vol.13 (1), p.271-271, Article 271

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) are quiescent, insensitive to BCR-ABL1 tyrosine kinase inhibitors (TKIs) and responsible for CML relapse. Therefore, eradicating quiescent CML LSCs is a major goal in CML therapy. Here, using a G
0
marker (G
0
M), we narrow down CML LSCs as G
0
M- and CD27- double positi...

Alternative Titles

Full title

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_c3477c962caf480e9537b3db7eabd49c

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c3477c962caf480e9537b3db7eabd49c

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-021-27928-8

How to access this item